Emcure Pharma Posts 38% Profit Growth in Q2

11 Nov 2024 , 11:43 AM

Emcure Pharmaceuticals reported a 38% year-on-year increase in Q2 net profit, reaching ₹202 Crore compared to ₹146 Crore in the same quarter last year. Revenue for Q2 rose by over 20%, totaling ₹2,002 Crore, driven by strong performance across segments.

International business posted a 25% growth YoY, with the Canadian market rising by 51% due to gains in core operations and subsidiary Mantra. The Rest of World markets grew by 29%, bolstered by strong contributions from both ARV and non-ARV products.

European market saw a steady 6% increase, mainly from base business growth. Domestic revenue increased by over 15% to ₹933 Crore, supported by strong base business and the Sanofi distribution partnership. EBITDA margin slightly declined, down 80 basis points to 20.8% in Q2, reflecting some operational pressures.

CEO Satish Mehta highlighted that Emcure’s recent investments in international and domestic segments are driving growth, with particular success in international markets.

Emcure’s partnerships, including the Sanofi agreement in India and Mantra acquisition in Canada, are now fully integrated, focusing on revenue and operational synergies. Looking forward, the company aims to boost margins through operational efficiencies, new product launches, and increased market share in both domestic and global markets.